PMID- 25368235
OWN - NLM
STAT- MEDLINE
DCOM- 20150109
LR  - 20221207
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 34
IP  - 11
DP  - 2014 Nov
TI  - Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
PG  - 6353-61
AB  - BACKGROUND/AIM: Chemoimmunotherapy has been used to treat intrahepatic 
      cholangiocarcinoma (ICC). However, little is known about the phenomena underlying 
      the immunomodulation of ICC cells elicited by chemoimmunotherapy. MATERIALS AND 
      METHODS: Primary ICC cells from a patient with ICC who received gemcitabine 
      followed by 5-fluorouracil (5-FU), both combined with dendritic cells pulsed with 
      Wilms' tumor 1 (WT1) peptides were cultured. ICC cells were treated with 
      gemcitabine, 5-FU or interferon (IFN)-gamma in vitro. The phenotype of the ICC cells 
      was examined by flow cytometry and quantitative reverse transcription polymerase 
      chain reaction. RESULTS: Stimulation of the ICC cells with gemcitabine resulted 
      in up-regulation of WT1 mRNA, programmed death receptor ligand-1 (PDL1) and 
      calreticulin. Gemcitabine, 5-FU and IFN-gamma induced up-regulation of mucin-1. 
      Moreover, human leukocyte antigen (HLA)-ABC, HLA-DR and PDL1 were extremely 
      up-regulated by IFN-gamma. CONCLUSION: Chemoimmunomodulating agents alter the 
      immunogenicity of ICC cells, resulting in complex clinical efficacy results.
CI  - Copyright(c) 2014 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Koido, Shigeo
AU  - Koido S
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Jikei University School of Medicine, Tokyo, Japan Institute of Clinical Medicine 
      and Research, Jikei University School of Medicine, Tokyo, Japan Department of 
      Oncology, Jikei University School of Medicine, Tokyo, Japan 
      shigeo_koido@jikei.ac.jp.
FAU - Kan, Shin
AU  - Kan S
AD  - Department of Oncology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Yoshida, Kosaku
AU  - Yoshida K
AD  - Research and Development Division, Tella Inc., Tokyo, Japan.
FAU - Yoshizaki, Shinji
AU  - Yoshizaki S
AD  - Research and Development Division, Tella Inc., Tokyo, Japan.
FAU - Takakura, Kazuki
AU  - Takakura K
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Namiki, Yoshihisa
AU  - Namiki Y
AD  - Institute of Clinical Medicine and Research, Jikei University School of Medicine, 
      Tokyo, Japan.
FAU - Tsukinaga, Shintaro
AU  - Tsukinaga S
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Odahara, Shunichi
AU  - Odahara S
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Kajihara, Mikio
AU  - Kajihara M
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Okamoto, Masato
AU  - Okamoto M
AD  - Department of Advanced Immunotherapeutics, Kitasato University School of 
      Pharmacy, Tokyo, Japan.
FAU - Ito, Masaki
AU  - Ito M
AD  - Department of Oncology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Yusa, Sei-Ichi
AU  - Yusa S
AD  - Research and Development Division, Tella Inc., Tokyo, Japan.
FAU - Gong, Jianlin
AU  - Gong J
AD  - Department of Medicine, Boston University School of Medicine, Boston, MA, U.S.A.
FAU - Sugiyama, Haruo
AU  - Sugiyama H
AD  - Department of Functional Diagnostic Science, Graduate School of Medicine, Osaka 
      University, Osaka, Japan.
FAU - Ohkusa, Toshifumi
AU  - Ohkusa T
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Homma, Sadamu
AU  - Homma S
AD  - Department of Oncology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Tajiri, Hisao
AU  - Tajiri H
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Jikei University School of Medicine, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Mucin-1)
RN  - 0 (RNA, Messenger)
RN  - 0 (WT1 Proteins)
RN  - 0 (WT1 protein, human)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 82115-62-6 (Interferon-gamma)
RN  - U3P01618RT (Fluorouracil)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - B7-H1 Antigen/genetics/metabolism
MH  - Bile Duct Neoplasms/immunology/pathology/*therapy
MH  - Bile Ducts, Intrahepatic/drug effects/*immunology/pathology
MH  - Cholangiocarcinoma/immunology/pathology/*therapy
MH  - Combined Modality Therapy
MH  - Dendritic Cells/*immunology
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Female
MH  - Fluorouracil/administration & dosage
MH  - HLA-DR Antigens/genetics/metabolism
MH  - Humans
MH  - *Immunotherapy
MH  - Interferon-gamma/administration & dosage
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Mucin-1/genetics/metabolism
MH  - Peritoneal Neoplasms/immunology/secondary/therapy
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tumor Cells, Cultured
MH  - WT1 Proteins/genetics/metabolism
MH  - Gemcitabine
OTO - NOTNLM
OT  - 5-fluorouracil
OT  - Gemcitabine
OT  - IFN-gamma
OT  - PDL1
OT  - WT1
OT  - chemoimmunotherapy
OT  - immunomodulation
EDAT- 2014/11/05 06:00
MHDA- 2015/01/13 06:00
CRDT- 2014/11/05 06:00
PHST- 2014/11/05 06:00 [entrez]
PHST- 2014/11/05 06:00 [pubmed]
PHST- 2015/01/13 06:00 [medline]
AID - 34/11/6353 [pii]
PST - ppublish
SO  - Anticancer Res. 2014 Nov;34(11):6353-61.